Elahere wins full approval for platinum-resistant ovarian cancer

FDA approved mirvetuximab soravtansine-gynx (Elahere) for adults with folate receptor alpha (FRα) positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer, who've received one to three prior systemic treatment regimens. The antibody-drug conjugate previously received accelerated approval for this indication. Efficacy was evaluated in the phase 3 MIRASOL trial involving 453 patients.